Name: Latest research reports of Mankind Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Mankind Pharma Ltd.

NSE: MANKIND | BSE: 543904 | ISIN: INE634S01028 | Industry: Pharmaceuticals
| Expensive Performer

2445.6000 -9.50 (-0.39%)

NSE Oct 21, 2025 15:31 PM

Volume: 35,115

Mankind Pharma Ltd.

01 Aug 2025

2445.60

-0.39%

Cost headwinds lead to earnings miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) reported in-line revenue in 1QFY26. However, EBITDA/PAT came in 5%/7% below our estimates.

Mankind Pharma Ltd. is trading below all available SMAs